Lead Product(s): Aducanumab
Therapeutic Area: Neurology Product Name: BIIB037
Highest Development Status: Phase III Product Type: Large molecule
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 09, 2020
Aducanumab, an amyloid beta-targeting antibody, has been shown in clinical trials to remove amyloid beta in the brain and significantly slow clinical decline in patients with Mild Cognitive Impairment (MCI) due to Alzheimer’s disease and mild Alzheimer’s disease dementia.
Lead Product(s): Undisclosed
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Discovery Platform Product Type: Small molecule
Recipient: Wren Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration November 30, 2020
The collaboration will use Wren’s network kinetics drug discovery platform, alongside Eisai’s extensive experience in drug discovery for neurodegenerative disorders, to accelerate the development of clinical candidates.